Showing results (111-120 of 626) with videos related to

Sort By:
Pageof 63
Eclinicalmedicine|July 31, 2026
Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challengesEsteban Ciliberti, Marta Nerone, Vincenza Ricco, et al.
Clinical Pharmacology : Advances and Applications|December 4, 2012
Pazopanib for the treatment of soft-tissue sarcomaPierre Heudel, Philippe Cassier, Olfa Derbel, et al.
Bulletin Du Cancer|June 2, 2015
[Initial management of advanced ovarian cancer: What radiological, pathological and surgical information are important for optimal therapeutic strategy?]Pierre-Etienne Heudel, Frédéric Selle, Philippe Morice, et al.
Journal of Assisted Reproduction and Genetics|July 6, 2018
Fertility preservation in women with cancer: a national study about French oncologists awareness, experience, and feelingsAmira Sallem, Joanna Shore, Isabelle Ray-Coquard, et al.
Cancer|October 26, 2006
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary sitePascal Seve, Isabelle Ray-Coquard, Veronique Trillet-Lenoir, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 31, 2023
The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinomaIsabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, et al.
Future Oncology (London, England)|August 31, 2023
NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancerSyrine Sghaier, Pauline Corbaux, Isabelle Ray-Coquard, et al.
Cancer Treatment Reviews|August 5, 2026
Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interceptionMylène Wespiser, Pauline Rochefort, Thibault Gauduchon, et al.
BMC Cancer|October 27, 2015
KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcomeMehdi Brahmi, Laurent Alberti, Armelle Dufresne, et al.
Gynecologic Oncology|March 22, 2003
Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimensIsabelle Ray-Coquard, Thomas Bachelot, Jean-Paul Guastalla, et al.
Pageof 63